Related Experiment Video
Updated: Jun 6, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary intervention
Giancarlo Marenzi1, Monica De Metrio, Mara Rubino
1Department of Cardiovascular Sciences, Centro Cardiologico Monzino, I.R.C.C.S, University of Milan, Milan, Italy. giancarlo.marenzi@ccfm.it
Insights
Acute hyperglycemia in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) significantly increases the risk of contrast-induced nephropathy (CIN) and in-hospital mortality.
Area of Science:
- Cardiology
- Nephrology
- Critical Care Medicine
Background:
- Acute hyperglycemia and contrast-induced nephropathy (CIN) are common in ST-elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI).
- Both conditions are linked to higher mortality rates.
- This study explores the relationship between acute hyperglycemia and CIN in this patient population.
Purpose of the Study:
- To investigate the association between acute hyperglycemia and the development of contrast-induced nephropathy (CIN).
- To assess the impact of acute hyperglycemia and CIN on in-hospital mortality in STEMI patients undergoing primary PCI.
Main Methods:
- Prospective enrollment of 780 STEMI patients undergoing primary PCI.
- Plasma glucose levels measured on admission; acute hyperglycemia defined as >198 mg/dL.
- CIN defined as a serum creatinine increase >25% within 72 hours.
Main Results:
- 19% of patients had acute hyperglycemia, and 14.5% developed CIN.
- Acute hyperglycemia was associated with a 2-fold higher incidence of CIN (27% vs 12%).
- Patients with acute hyperglycemia and those with CIN had significantly higher in-hospital mortality rates (12% vs 3% and 27% vs 0.9%, respectively).
- Acute hyperglycemia independently predicted both CIN and in-hospital mortality.
Conclusions:
- Acute hyperglycemia is a significant risk factor for CIN in STEMI patients undergoing primary PCI.
- Acute hyperglycemia is associated with increased in-hospital mortality in this patient group.
- The combination of acute hyperglycemia and CIN presents the highest mortality risk.
Background:
Acute hyperglycemia and contrast-induced nephropathy (CIN) are frequently observed in ST-elevation acute myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI), and both are associated with an increased mortality rate. We investigated the possible association between acute hyperglycemia and CIN in patients undergoing primary PCI.
Methods:
We prospectively enrolled 780 STEMI patients undergoing primary PCI. For each patient, plasma glucose levels were assessed at hospital admission. Acute hyperglycemia was defined as glucose levels>198 mg/dL (11 mmol/L). Contrast-induced nephropathy was defined as an increase in serum creatinine>25% from baseline in the first 72 hours.
Results:
Overall, 148 (19%) patients had acute hyperglycemia; and 113 (14.5%) patients developed CIN. Patients with acute hyperglycemia had a 2-fold higher incidence of CIN than those without acute hyperglycemia (27% vs 12%, P<.001). In-hospital mortality was higher in patients with acute hyperglycemia than in those without acute hyperglycemia (12% vs 3%, P<.001). Mortality rate was also higher in patients developing CIN than in those without this renal complication (27% vs 0.9%, P<.001). Patients with acute hyperglycemia that developed CIN had the highest mortality rate (38%). Acute hyperglycemia was an independent predictor of CIN and in-hospital mortality.
Conclusions:
In STEMI patients undergoing primary PCI, acute hyperglycemia is associated with an increased risk for CIN and with increased in-hospital mortality.
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Diabetic Nephropathy
Imaging Studies VII: Vascular Imaging
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Pancreatitis II: Clinical Manifestations and Management
Hyperglycemia
